# Arcturus Therapeutics Holdings Inc. (ARCT) fundamentals

Data as of 2026-11-05. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.40, market value $267 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Arcturus Therapeutics Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9.1×**. Each dollar of revenue is priced at 9.1×.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -27.3%** (5-yr avg -13.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -348.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -80.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -30.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -340.9%**. Return on all capital, debt included, is -340.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -34.4%**. Each dollar of assets produces -34.4% of profit.

## Growth
- **Revenue growth (1 yr): -46.1%** (3-yr -26.4%/yr, 5-yr 53.8%/yr). Revenue fell 46.1% over the last year, against 53.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 20.0%**. Earnings per share rose 20.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.19**. Debt is 0.19 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.9×**. It would take 1.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 6.64** (quick 6.64). Current assets cover the next year's liabilities 6.64 times.
- **Altman Z-score: 4.63**. A Z-score of 4.63 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Arcturus Therapeutics Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 21.7%** (YTD 77.3%, 3-mo 73.6%). The shares are up 21.7% over twelve months including dividends.
- **From 52-week high: -47.7%** (70.9% above the low). Trading 48% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 2.13** (volatility 80%). Beta of 2.13 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARCT · Page: https://foliofundamentals.com/stocks/arct

Not investment advice.